Tests escitalopram in adults with asthma that flares up often
Compares escitalopram with a placebo in adults who have frequent asthma flare-ups.
Plain-language title generated from the registry record
Registry title: Escitalopram in Asthma Patients With Frequent Exacerbation
Key facts
- Where
- Dallas, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06216535, who can take part
Where in United States
- UT Southwestern, 1440 Empire Central, Ste. LD4.100Dallas, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Texas Southwestern Medical Center
- Trial code
- NCT06216535
- Record updated
- 26 January 2026
- Original description
Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), such as escitalopram are widely used for mood and anxiety disorders. However, they have also been explored, with promising findings, for a variety of disorders outside of psychiatry. Clinical studies of SSRIs in depressed people with asthma were associated with decreased asthma exacerbations and improvement in asthma control. In this study, the number of asthma exacerbations will be assessed as the primary outcome measure in patients using escitalopram vs. placebo.Read full original descriptionShow less
Escitalopram in Asthma Patients With Frequent Exacerbation
Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), such as escitalopram are widely used for mood and anxiety disorders. However, they have also been explored, with promising findings, for a variety of disorders outside of psychiatry. Clinical studies of SSRIs in depressed people with asthma were associated with decreased asthma exacerbations and improvement in asthma control. In this study, the number of asthma exacerbations will be assessed as the primary outcome measure in patients using escitalopram vs. placebo.
Inclusion: Moderate to severe persistent asthma; Treatment with medium to high dose ICS and LABA therapy; Three or more severe asthma exacerbations (requiring ≥ 3 days of systemic corticosteroids) in the past year; Age 18-75 years old, male or female sex, English or Spanish speaking; Participants will be required to be clinically stable with no recent exacerbations, infections or changes in asthma controller therapy for at least 4 weeks before study entry; Biologic therapy for asthma (e.g., omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab) will be allowed if started at least 6 months prior to randomization.
Exclusion: Currently taking an antidepressant (antidepressants that are not SSRIs nor SNRIs prescribed for an indication other than depression at subtherapeutic doses are acceptable); Current substance use disorder and/or current tobacco use or greater than 10 pack-years lifetime use; A current MDD episode as well as bipolar disorder, schizophrenia, or schizoaffective disorder; Severe or life-threatening medical illness that would make completion of study unlikely or clinically significant laboratory or ECG findings at baseline; Vulnerable populations including intellectual disability or other severe cognitive impairment, inmates, pregnant or nursing women or women of childbearing age who will not use UT Southwestern IRB-approved methods of birth control or abstinence during the study; High risk for suicide defined as > 1 past suicide attempts or any attempt within the past 12 months.